PetMed Express (PETS) received on July 2, an expected notice from The Nasdaq Stock Market indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended March 31, with the Securities and Exchange Commission, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days, or until September 1, and following receipt of such plan, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-K due date, or until December 29, for the Company to regain compliance. On June 16, the Company filed a Notification of Late Filing on Form 12b-25 indicating that it was unable, without unreasonable effort or expense, to file its Form 10-K by the prescribed due date because the Company is continuing to compile, review, and analyze the information necessary to complete its financial statements and related disclosures to be included in the Form 10-K, as more fully described in the Company’s Current Report on Form 8-K filed with the SEC on July 1. While the Company can provide no assurances as to timing, the Company is working diligently to complete its financial statements for its fiscal year ending March 31, and the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Listing Rule.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PETS:
- PetMed Express Delays Annual Report Amid Investigations
- PetMed Express says unable to file 2025 Form 10-K within extension period
- PetMed Express options imply 21.6% move in share price post-earnings
- PetMed Express options imply 11.7% move in share price post-earnings
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz